Sorin Group just won European regulatory go-ahead to introduce its CROWN PRT stented aortic heart valve. The prosthesis features Phospholipid Reduction Treatment (PRT) that’s designed to reduce calcification by reducing the phospholipid content on the valve. The PRT technology is already available in the U.S., but on Sorin’s Mitroflow aortic valve.
The company touts improved modifications available on the new valve that help short rinse time and provide for easier placement by the surgeon, in part thanks to radiopaque markers.
Research has demonstrated that phospholipids play a key role in the calcification process of bioprotheses and Sorin’s patented Phospholipid Reduction Treatment (PRT) has been shown to decrease phospholipid content in pericardial tissue thus leading to a remarkable reduction of calcium uptake compared to control.
“We are eagerly looking forward to implanting CROWN PRT, as this valve incorporates all the latest technological advancements in a modern bioprosthesis, enabling cardiac surgery procedures that are simple, reliable and reproducible,” said Professor Alain Leguerrier, Chief of the Cardio Thoracic and Vascular Surgery Department, Centre Hospitalier Universitaire de Rennes, France. “CROWN PRT meets all the conditions for a remarkable hemodynamic performance and an optimized durability.”